Merck Announces Third-Quarter 2013 Financial Results

Dateline City: WHITEHOUSE STATION, N.J. 2013 Third-Quarter Non-GAAP EPS of $0.92, Excluding Certain Items; GAAP EPS of $0.38 Worldwide Sales were $11.0 Billion, a Decrease of 4 Percent Reflecting the Unfavorable Impact of Patent Expiries and a 2 Percent Negative Impact from Foreign Exchange Strong Growth in Vaccines and Immunology as well as ISENTRESS ‘Breakthrough Therapy’ Designation Granted for MK-5172/MK-8742, in Development for the Treatment of Chronic Hepatitis C Virus Infection; V503, Merck’s Investigational 9-valent HPV Vaccine has Completed Pivotal Phase III Study, on Track for 2013 Submission Narrows Full-Year Non-GAAP EPS Target to $3.48 to $3.52; GAAP EPS Target to $1.61 to $1.79 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2013.     $ in millions, except EPS amounts   ThirdQuarter2013   ThirdQuarter20...
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news